Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
News for ASAHI KAISEI CRP UNSP/ADR (AHKSY) reflects the breadth of Asahi Kasei Corporation’s activities across its Healthcare, Homes, and Material sectors. Company announcements highlight how this diversified manufacturer is reshaping its portfolio, advancing medical technologies, and developing new materials and electronic components.
In Healthcare, recent news features ZOLL Medical, an Asahi Kasei company, and its LifeVest wearable cardioverter defibrillator. Updates describe launches of next-generation LifeVest systems and garments, along with references to clinical evidence and AI-enhanced algorithms designed to reduce false alarms. Asahi Kasei Pharma also appears in news items, including the planned relocation of its global R&D hub to Shonan Health Innovation Park to strengthen drug discovery and open innovation.
Within the Material sector, news coverage includes Asahi Kasei Microdevices (AKM) and its sensing technologies, such as millimeter-wave radar solutions for real-time swallowing detection, gesture recognition based on electromyography, and AgeTech and PetTech applications like fall detection, smart diapers, cage monitoring systems, and smart pet collars. Other articles highlight advanced materials, including PIMEL™ photosensitive dielectric recognized by a TSMC Excellent Performance Award, and battery-related innovations such as high ionic conductive electrolyte technology licensed to EAS Batteries.
Investors and followers of AHKSY can use this news stream to track Asahi Kasei’s portfolio transformation under its "Trailblaze Together" plan, including structural reforms like the divestiture of the Daramic lead battery separator business, the planned phase-out of hexamethylene diamine production, and the integration of Asahi Kasei Advance with Teijin Frontier. Bookmark this page to monitor ongoing developments in pharmaceuticals, critical care, electronics, advanced materials, and sustainability-related initiatives that Asahi Kasei highlights in its public communications.
ZOLL Medical Corporation has successfully completed its acquisition of Itamar Medical Ltd. for $1.0333 per ordinary share, totaling approximately $31 per American Depository Share. Itamar Medical will operate as a division within ZOLL, focusing on sleep-disordered breathing diagnostics. The integration is expected to leverage ZOLL's global infrastructure to drive growth while maintaining operations in Caesarea, Israel. Following the acquisition, Itamar Medical's shares will cease trading on the Nasdaq and TASE markets, and it will deregister its securities with the SEC.
Summary not available.
ZOLL Medical Corporation has announced a definitive agreement to acquire Itamar Medical Ltd. for approximately $538 million. This acquisition will enable ZOLL to enhance its services for undiagnosed cardiac patients suffering from sleep apnea. Itamar’s WatchPAT device, which is FDA-cleared, is a key component in this integration to improve diagnosis and treatment in the cardiopulmonary sector. The deal represents a premium of 50.2% over Itamar's stock price on September 10, 2021, and is expected to close by the end of 2021.